Skip to main content

Table 1 Predicted reduction in lifetime risk of cancer with the prototype contraceptive

From: Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists

 

Duration of regimen (years)

Cancer type

5

10

15

Breast

31%

53%

70%

Endometrium

18%

33%

45%

Ovary

41%

67%

84%

  1. The calculations were made using the model described by Pike [12], and were based on using the regimen at any time after the first full-term pregnancy and before age 40 years.